Why Vanda Pharmaceuticals Inc. Shares Tumbled

Vanda Pharmaceuticals gets clobbered after reporting a wider-than-expected first-quarter loss. Is this dip a buying opportunity or a reason to stay away?

May 8, 2014 at 10:35AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Vanda Pharmaceuticals (NASDAQ:VNDA), a biopharmaceutical company focused on developing pharmaceutical products to treat non-24-hour disorder and schizophrenia, tumbled as much as 23% after reporting worse-than-expected first-quarter results.

So what: For the quarter, Vanda reported total revenue of $9.1 million, a 12% increase from the $8.1 million reported in the year-ago period. Its current quarter included $1.7 million in Fanapt royalty revenue, as well as $7.5 million in amortized royalty revenue tied to the $200 million upfront payment received from Novartis for U.S. and Canadian rights to Fanapt. Operating expenses for the quarter exploded higher to $35.7 million from $12.6 million in the year-ago period, mostly tied to the upcoming launch of Hetlioz, the company's non-24-hour disorder drug in the U.S. Net loss for the quarter widened by just shy of 490% to $26.5 million, or $0.79 per share, compared to a loss of just $4.5 million, or $0.16 per share in the year-ago period. By comparison, Wall Street expected a considerably narrower $0.30 per share loss.

Now what: Vanda shareholders have to enjoy the company's well-capitalized position ($100.4 million in cash, cash equivalents, and marketable securities), but its earnings flops and inability to benefit in any meaningful way from Fanapt are still front and center in the minds of investors. The hope here is that Hetlioz, which has no competition and is preparing to launch in the U.S., can deliver sustainable revenue growth and profits to Vanda. Still, even with Hetlioz, it could be two or three years before Vanda is able to turn the corner to profitability. As such, and keeping in mind its lack of success with Fanapt, I'd suggest investors not be lured in by today's dip and look for more intriguing growth opportunities elsewhere within the biotech sector.

Vanda shares may have soared over the past year, but it'll likely have a hard time keeping pace with this top stock over the long run
Give me five minutes, and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information